PMID- 38295658 OWN - NLM STAT- MEDLINE DCOM- 20240214 LR - 20240214 IS - 1618-095X (Electronic) IS - 0944-7113 (Linking) VI - 125 DP - 2024 Mar TI - Efficacy and safety of Shenqi Fuzheng injection combined with chemotherapy for cancer: An overview of systematic reviews. PG - 155293 LID - S0944-7113(23)00651-7 [pii] LID - 10.1016/j.phymed.2023.155293 [doi] AB - BACKGROUND: In China, Shenqi Fuzheng injection (SFI) has been used as an adjuvant therapy to treat all kinds of cancer for many years. A large number of systematic reviews or meta-analyses (SRs/MAs) were published to assess its efficacy and safety in the past few years. However, the quality of SRs/MAs was unclear and did not generate high-quality clinical evidence. OBJECTIVE: We conducted an overview to integrate relevant SRs/MAs published in the past with the aim of providing new clinical evidence for SFI in combination with chemotherapy in the treatment of cancer. OBJECTIVE: We conducted an overview to integrate relevant SRs/MAs published in the past with the aim of providing new clinical evidence for SFI in combination with chemotherapy in the treatment of cancer. METHODS: A comprehensive search of PubMed, Web of Science, Embase, the Cochrane Library, CNKI, VIP, WanFang, and CBM was performed from the database inception to September 30, 2023. SRs/MAs of randomized controlled trials (RCTs) on SFI combined with chemotherapy for cancer were included. Four reviewers screened the literature and extracted relevant information. Five reviewers assessed the quality of reporting, methodological quality, risk of bias, and quality of evidence for SRs/MAs. We used corrected covered area (CCA) to assess the degree of overlap among the RCTs included in SRs/MAs. We performed a descriptive analysis for the results of the included SRs/MAs. RESULTS: A total of 32 SRs/MAs of SFI combined with chemotherapy for cancer were included. We assessed the reporting quality of SRs/MAs using the PRISMA 2020 statement. 1 SR/MA had relatively complete reports, 20 SRs/MAs had some deficiencies in reporting, and 11 SRs/MAs had serious deficiencies in reporting. We assessed the methodological quality of SRs/MAs using the AMSTAR 2 tool. The methodological quality of all SRs/MAs was very low. We assessed the risk of bias for SRs/MAs using the ROBIS tool. The risk of bias was low for 19 SRs/MAs and unclear for 13 SRs/MAs. We assessed the quality of evidence for SRs/MAs using the GRADE evidence quality evaluation system. 50 items were moderate quality, 46 items were low quality, 27 items were very low quality, and 85 items were unclear. SFI combined with chemotherapy played a role in increasing efficacy and decreasing toxicities in all kinds of cancer, including clinical efficacy (except liver cancer), quality of life, immune function (except CD8+), leukopenia, thrombocytopenia, hemoglobinopenia, nausea and vomiting, liver damage, kidney damage, neurotoxicity, alopecia, and diarrhea. CONCLUSION: The overview showed that SFI combined with chemotherapy may improve clinical efficacy (except for liver cancer), quality of life, and immune (except for CD8+) function in all types of cancer, as well as adverse events (AEs) such as leukopenia, thrombocytopenia, etc. Since most of the clinical evidence was low, higher quality clinical trials will be expected to improve the reliability of the above conclusions in the future. CI - Copyright (c) 2023 The Author(s). Published by Elsevier GmbH.. All rights reserved. FAU - Chen, Guang AU - Chen G AD - Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, No. 31, West Huanghe Road, Yunhe District, Cangzhou, Hebei 061012, China; College of Traditional Chinese Medicine, Hebei University, Baoding, Hebei 071000, China. FAU - Lu, Jiawei AU - Lu J AD - Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, No. 31, West Huanghe Road, Yunhe District, Cangzhou, Hebei 061012, China; Graduate School, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050091, China. FAU - Li, Boyao AU - Li B AD - Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, No. 31, West Huanghe Road, Yunhe District, Cangzhou, Hebei 061012, China; College of Traditional Chinese Medicine, North China University of Science and Technology, Tangshan, Hebei 063210, China. FAU - Zhao, Mengsha AU - Zhao M AD - Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, No. 31, West Huanghe Road, Yunhe District, Cangzhou, Hebei 061012, China; College of Traditional Chinese Medicine, North China University of Science and Technology, Tangshan, Hebei 063210, China. FAU - Liu, Di AU - Liu D AD - Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, No. 31, West Huanghe Road, Yunhe District, Cangzhou, Hebei 061012, China; College of Traditional Chinese Medicine, North China University of Science and Technology, Tangshan, Hebei 063210, China. FAU - Yang, Zongyu AU - Yang Z AD - Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, No. 31, West Huanghe Road, Yunhe District, Cangzhou, Hebei 061012, China. Electronic address: 15832781820@163.com. FAU - Liu, Fei AU - Liu F AD - Hebei Province Cangzhou Hospital of Integrated Traditional and Western Medicine, No. 31, West Huanghe Road, Yunhe District, Cangzhou, Hebei 061012, China. Electronic address: liufei_527@163.com. LA - eng PT - Journal Article DEP - 20231223 PL - Germany TA - Phytomedicine JT - Phytomedicine : international journal of phytotherapy and phytopharmacology JID - 9438794 RN - 0 (shenqi fuzheng) RN - 0 (Drugs, Chinese Herbal) SB - IM MH - Humans MH - *Carcinoma, Non-Small-Cell Lung/drug therapy MH - *Liver Neoplasms MH - *Lung Neoplasms/drug therapy MH - *Leukopenia MH - *Thrombocytopenia MH - *Drugs, Chinese Herbal OTO - NOTNLM OT - Cancer OT - Chemotherapy OT - Chinese herbal injection OT - Overview OT - Systematic reviews OT - Traditional Chinese medicine COIS- Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. EDAT- 2024/02/12 05:43 MHDA- 2024/02/12 05:44 CRDT- 2024/01/31 18:11 PHST- 2023/11/20 00:00 [received] PHST- 2023/12/16 00:00 [accepted] PHST- 2024/02/12 05:44 [medline] PHST- 2024/02/12 05:43 [pubmed] PHST- 2024/01/31 18:11 [entrez] AID - S0944-7113(23)00651-7 [pii] AID - 10.1016/j.phymed.2023.155293 [doi] PST - ppublish SO - Phytomedicine. 2024 Mar;125:155293. doi: 10.1016/j.phymed.2023.155293. Epub 2023 Dec 23.